Over and above, since MMR deficiency predicts response to checkpoint blockade in 12 different solid tumor types45, further studies using genetically engineered mouse models46 could help to identify molecular determinants that make not only CRC tumors sensitive to immune checkpoint blockade, but possibly also other tumor types. This evidence concerns the gene MRC1 and hyperinsulinemic hypoglycemia, familial, 4.